Overall, the results reported herein show that downregulation of HSP90 expression in preclinical HER2+ breast cancer models in vitro impairs the anti-tumor activity of trastuzumab- and trastuzumab/pertuzumab-based combinations with chemotherapy and hormonal treatment. Here, ERBB2 is linked to breast cancer.